1. Spencer, TJ, Biederman, J, Madras, BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005; 57: 1293–1300.
3. Solanto, MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res. 2002; 130: 65–71.
4. Fusar-Poli, P, Rubia, K, Rossi, G, Sartori, G, Balottin, U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012; 169: 264–272. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2011.11060940. Accessed January 16, 2017.
5. Volkow, ND, Wang, GJ, Newcorn, J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. NeuroImage. 2007; 34: 1182–1190.
6. Steve, L. An Introduction to the Event-Related Potential Technique. Cambridge: MIT Press; 2005.
8. Szuromi, B, Czobor, P, Komlósi, S, Bitter, I. P300 deficits in adults with attention deficit hyperactivity disorder: a meta-analysis. Psychol Med. 2011; 41(7): 1529–1538. Epub ahead of print Oct 20, 2010.
9. Barry, RJ, Clarke, AR, Johnstone, SJ. A review of electrophysiology in attention-deficit/hyperactivity disorder, I: qualitative and quantitative electroencephalography. Clin Neurophysiol. 2003; 114(2): 171–183.
10. Barry, RJ, Johnstone, SJ, Clarke, AR. A review of electrophysiology in attention-deficit/hyperactivity disorder, II: event-related potentials. Clin Neurophysiol. 2003; 114(2): 184–198.
11. Chen, KC, Lee, IH, Yang, YK, et al. P300 waveform and dopamine transporter availability: a controlled EEG and SPECT study in medication-naive patients with schizophrenia and a meta-analysis. Psychol Med. 2014; 44(10): 2151–2162. Epub ahead of print Nov 15, 2013.
12. Chen, KC, Yang, YK, Howes, O, et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [99mTc]-TRODAT-1 and a meta-analysis. Schizophr Bull. 2013; 39(2): 378–386. Epub ahead of print Dec 8, 2011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576153/. Accessed January 16, 2017.
13. Chen, PS, Yeh, TL, Lee, IH, et al. Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers: a SPECT study. NeuroImage. 2011; 56(3): 1526–1530. Epub ahead of print Mar 1.
14. Hwang, WJ, Yao, WJ, Wey, SP, Ting, G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med. 2004; 45(2): 207–213. http://jnm.snmjournals.org/content/45/2/207.long. Accessed January 16, 2017.
15. Picton, TW, Bentin, S, Berg, P, et al. Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria. Psychophysiology. 2000; 37(2): 127–152.
16. Wechsler, D.
Wechsler Adult Intelligence Scale–Revised Manual
anglicized, ed London: Psychological Corporation; 1986.
17. Kessler, RC, Ustun, TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res. 2004; 13(2): 93–121.
18. Kessler, RC, Adler, L, Ames, M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005; 35(2): 245–256.
19. Yeh, CB, Gau, SS, Kessler, RC, Wu, YY. Psychometric properties of the Chinese version of the adult ADHD Self-Report Scale. Int J Methods Psychiatr Res. 2008; 17(1): 45–54.
20. Cohen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Milton Park, NJ: Lawrence Erlbaum Associates; 1988.
21. Hesse, S, Ballaschke, O, Barthel, H, Sabri, O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res. 2009; 171(2): 120–128. Epub ahead of print Jan 26.
23. Wang, GJ, Volkow, N, Wigal, T, et al. Chronic treatment with methylphenidate increases dopamine transporter density in patients with attention deficit hyperactive disorder. J Nucl Med. 2009; 50(Suppl. 2): 1283.
24. Ford, JM, Sullivan, EV, Marsh, L, White, PM, Lim, KO, Pfefferbaum, A. The relationship between P300 amplitude and regional gray matter volumes depends upon the attentional system engaged. Electroencephalogr Clin Neurophysiol. 1994; 90(3): 214–228.
26. Gershon, J, Gershon, J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002; 5(3): 143–154.
27. Roessner, V, Sagvolden, T, Dasbanerjee, T, et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience. 2010; 167(4): 1183–1191. Epub ahead of print Mar 6.
28. Hannestad, J, Gallezot, JD, Planeta-Wilson, B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010; 68(9): 854–860. Epub ahead of print Aug 5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742016/. Accessed January 16, 2017.
29. Wang, GJ, Volkow, ND, Wigal, T, et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS One. 2013; 8(5): e63023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655054/. Accessed January 16, 2017.